The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
Don't look for it in Rome... Nearly two months on, the Commission’s DMA non-compliance decision against Meta was finally published... -
From the Strait of Messina, where Scylla and Charybdis lurked, to an imaginary Strait of Leipzig, where a judge has just awarded damages t... -
Video here. [The name AFA makes me nostalgic even of the Chicago School: same with you?]
-
Here . Listened to it at least twice - fresh air for Rome's hot summer!
-
Time for comments closed! Thank you for your great ones, Wavesblog Readers and beyond! Revising and updating it right now. Peer Reviewers ar...
-
WSJ, here . Competition authorities are a bit distracted, as of late. Too little of real value or impact has been learned or done. Those w...